From Public Funds To VCs: Swiss Financing For Swiss Biotech

Innovation Grants And Mid-Stage Raises

 
• By Ayisha Sharma

While most of the cash for Swiss biotech firms comes from outside the country, around 20% is provided by Swiss entities. Scrip spoke with two of these home-grown supporters of life sciences innovation about the move from academia to industry and their respective investment strategies.      

Innovation Agencies And Domestic VCs Are Backing Swiss Firms • Source: Shutterstock

Despite the macroeconomic challenges that have beset the global life sciences sector, biotech firms in Switzerland together raised more than CHF1.3bn ($1.45bn) in 2022 according to the Swiss Biotech Association’s latest annual report. Around CHF780m of this was collected by public companies with the remaining CHF550m collected by privately held firms.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

More from Business